These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39195312)

  • 1. Prior Negative Biopsy, PSA Density, and Anatomic Location Impact Cancer Detection Rate of MRI-Targeted PI-RADS Index Lesions.
    Alzubaidi AN; Zheng A; Said M; Fan X; Maidaa M; Owens RG; Yudovich M; Pursnani S; Owens RS; Stringer T; Tracy CR; Raman JD
    Curr Oncol; 2024 Aug; 31(8):4406-4413. PubMed ID: 39195312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Accuracy of MRI-Ultrasound Fusion Targeted Biopsy Based on PI-RADS v2.1 Category in Transition/Peripheral Zone of the Prostate.
    Liu Y; Wang S; Xu G; Zhou B; Zhang Y; Ye B; Xiang L; Zhang Y; Xu H
    J Magn Reson Imaging; 2023 Sep; 58(3):709-717. PubMed ID: 36773016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.
    Brizmohun Appayya M; Sidhu HS; Dikaios N; Johnston EW; Simmons LA; Freeman A; Kirkham AP; Ahmed HU; Punwani S
    Br J Radiol; 2018 Feb; 91(1083):20170645. PubMed ID: 29189042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-Adapted Strategy Combining Magnetic Resonance Imaging and Prostate-Specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 ``Gray Zone'' Lesions.
    Akpinar C; Oz DK; Oktar A; Suer E; Ozden E; Haliloglu N; Gulpinar O; Gokce MI; Gogus C; Baltaci S
    Clin Genitourin Cancer; 2024 Jun; 22(3):102071. PubMed ID: 38555682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
    Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
    Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilizing lesion diameter and prostate specific antigen density to decide on magnetic resonance imaging guided confirmatory biopsy of prostate imaging reporting and data system score three lesions in African American prostate cancer patients managed with active surveillance.
    Alanee S; Deebajah M; Dabaja A; Peabody J; Menon M
    Int Urol Nephrol; 2022 Apr; 54(4):799-803. PubMed ID: 35138582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Magnetic Resonance Imaging/Ultrasound-guided Target Biopsy in Detecting Clinically Significant Prostate Cancer.
    Kurokawa G; Mori K; Sasaki H; Nakano J; Takahashi Y; Iwatani K; Urabe F; Tsuzuki S; Koike Y; Sato S; Takahashi H; Miki K; Kimura T
    Anticancer Res; 2024 Feb; 44(2):679-686. PubMed ID: 38307559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
    Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
    Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive MRI-TRUS fusion-targeted prostate biopsy according to PI-RADS classification in patients with prior negative systematic biopsy results.
    Lai WJ; Wang HK; Liu HT; Park BK; Shen SH; Lin TP; Chung HJ; Huang YH; Chang YH
    J Chin Med Assoc; 2016 Nov; 79(11):618-624. PubMed ID: 27567440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should Targeted Biopsy be Performed in Patients Who Have Only Pi-rads 3 Lesions?
    Koparal MY; Sözen TS; Karşiyakali N; Akdoğan B; Özen H; Aslan G; Türkeri L
    Arch Esp Urol; 2022 Jun; 75(5):410-415. PubMed ID: 35983811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
    Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
    BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer.
    Frisbie JW; Van Besien AJ; Lee A; Xu L; Wang S; Choksi A; Afzal MA; Naslund MJ; Lane B; Wong J; Wnorowski A; Siddiqui MM
    Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):347-352. PubMed ID: 35523940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
    Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
    Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies.
    Hamm CA; Baumgärtner GL; Padhani AR; Froböse KP; Dräger F; Beetz NL; Savic LJ; Posch H; Lenk J; Schallenberg S; Maxeiner A; Cash H; Günzel K; Hamm B; Asbach P; Penzkofer T
    Eur Radiol; 2024 Oct; 34(10):6229-6240. PubMed ID: 38538841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.
    Hansen NL; Kesch C; Barrett T; Koo B; Radtke JP; Bonekamp D; Schlemmer HP; Warren AY; Wieczorek K; Hohenfellner M; Kastner C; Hadaschik B
    BJU Int; 2017 Nov; 120(5):631-638. PubMed ID: 27862869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
    Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
    Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.